Trial Profile
Phase II multicenter,open-label, clinical and pharmacokinetic study of Aplidin as a 3-hour infusion every 2 weeks, in patients with advanced or metastatic transitional cell carcinoma of the urothelium, relapsing or progressing after first line chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Plitidepsin (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- Sponsors PharmaMar
- 07 Apr 2022 Status changed from recruiting to completed.
- 10 Jun 2011 New trial record